Table 2.
Response rates among combination erlotinib and fulvestrant versus erlotinib alone
| Erlotinib and Fulvestrant |
Erlotinib Alone |
*P value | ||
|---|---|---|---|---|
| All Patients | ||||
| ORR (%) | 11 (16.4) | 4(12.1) | 0.77 | |
| PR (% | 11 (16.4) | 4(12.1) | ||
| SD (%) | 18 (27) | 7 21) | ||
| PD (%) | 25 (37) | 16 (46) | ||
| NA (%) | 13 (19) | 6 (18) | ||
| Total | 67 | 33 | ||
| EGFR Wild Type | ||||
| ORR (%) | 2(5.1) | 0 (0) | >0.99 | |
| PR (% | 2 (5.1) | 0 (0) | ||
| SD (%) | 14 (36) | 1(8) | ||
| PD (%) | 15 (38) | 11 (92) | ||
| NA (%) | 8 (21) | 0 (0) | ||
| Total | ||||
| ORR (%) | 3 (7.7) | 0 (0) | >0.99 | |
| PR (% | 3 (7.7) | 0 (0) | ||
| SD (%) | 14 (36) | 1 (8) | ||
| PD (%) | 15 (38) | 11 (92) | ||
| NA (%) | 7 (18) | 0 (0) | ||
| Total | 39 | 12 | ||
| CBR (%) | 16 (41.1) | 1 (8.3) | 0.04 | |
| PR + SD (%) | 16 (41.1) | 1 (8.3) | ||
| PD (%) | 15 (38) | 11 (92) | ||
| NA | 8 (21) | 0 (0) | ||
| Total | 39 | 12 | ||
*
Fisher’s exact test.
ORR: objective response rate, which includes confirmed responses only, RR: response rate, which includes confirmed or unconfirmed responses, CBR: clinical benefit rate which is defined as SD plus PR, NA: not available, PR: Partial Response, SD: Stable Disease, PD: Progressive Disease